2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Nom du produit CAS No. Pureté Chemical Structure
  • HY-15486R
    Salubrinal (Standard) 405060-95-9 98%
    Salubrinal (Standard) is the analytical standard of Salubrinal. This product is intended for research and analytical applications. Salubrinal is a cell-permeable and selective inhibitor of eIF2α dephosphorylation. Salubrinal acts as a dual-specificity phosphatase 2 (Dusp2) inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis. Salubrinal has antiviral activity against HSV-1 and inhibits dephosphorylation of eIF2α mediated by the HSV-1 protein ICP34.5.
    Salubrinal (Standard)
  • HY-15495B
    (3S)-Tanzisertib hydrochloride 2517855-91-1
    (3S)-Tanzisertib (hydrochloride) ((3S)-CC-930 (hydrochloride)) is an orally active JNK inhibitor (IC50 values for JNK1, JNK2, and JNK3 are 61, 7, and 6 nM, respectively). (3S)-Tanzisertib (hydrochloride) selectively inhibits ERK1, p38α, and EGFR (IC50 = 0.48, 3.4, and 0.38 μM, respectively). (3S)-Tanzisertib (hydrochloride) inhibits LPS-induced TNFα production in an acute rat PK-PD model. (3S)-Tanzisertib (hydrochloride) can be used in idiopathic pulmonary fibrosis (IPF) research.
    (3S)-Tanzisertib hydrochloride
  • HY-15505R
    RWJ-67657 (Standard) 215303-72-3
    RWJ-67657 (Standard) is the analytical standard of RWJ-67657. This product is intended for research and analytical applications. RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity.
    RWJ-67657 (Standard)
  • HY-155169
    hLTA4H/hLTA4S-IN-1 128253-12-3 98%
    hLTA4H/hLTA4S-IN-1 is a possible dual inhibitor that has the activity of inhibiting both human leukotriene hydrolase (hLTA4H) and human leukotriene C4 synthase (hLTC4S). hLTA4H/hLTA4S-IN-1 was identified by computer-assisted methods and is able to effectively interfere with the leukotriene biosynthesis pathway in cells. hLTA4H/hLTA4S-IN-1 can be used to study inflammatory responses.
    hLTA4H/hLTA4S-IN-1
  • HY-155364
    Antimicrobial agent-26 3026743-44-9 98%
    Antimicrobial agent-26 is a potent antimicrobial agent and can mitigate antibiotic resistancein vitro.
    Antimicrobial agent-26
  • HY-15538R
    Ebrotidine (Standard) 100981-43-9 98%
    Ebrotidine (Standard) is the analytical standard of Ebrotidine. This product is intended for research and analytical applications. 0
    Ebrotidine (Standard)
  • HY-155407
    ALR-6 6621-92-7 98%
    ALR-6 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-6 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM and has no significant effect on direct inhibition of 5-LOX.
    ALR-6
  • HY-155408
    ALR-27 903639-13-4 98%
    ALR-27 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-27 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM, with no significant direct inhibition of 5-LOX. ALR-27 not only reduces prostaglandin and leukotriene (LT) production in neutrophils but also increases the production of specialized prolytic mediators in specific human macrophage phenotypes.
    ALR-27
  • HY-155494
    trans-Stilbene-NHCO-(CH2)3-acid 316173-40-7 98%
    trans-Stilbene-NHCO-(CH2)3-acid, a trans-stilbene hapten, can be used to elicit a panel of monoclonal antibodies that display a range of fluorescent spectral behavior.
    trans-Stilbene-NHCO-(CH2)3-acid
  • HY-155495
    (±)-Bupropion-(CH2)3-OH hydrochloride 80762-38-5 98%
    (±)-Bupropion-(CH2)3-OH hydrochloride (compound 3) is a hapten useful in the radioimmunoassay of Bupropion (HY-B0403).
    (±)-Bupropion-(CH2)3-OH hydrochloride
  • HY-155517
    INF200 3049730-43-7 98%
    INF200 (compound 5) is a sulfonylurea-based inhibitor of NLRP3 and NLRP3-mediated pyroptosis. INF200 has beneficial cardiometabolic effects in rat model of high-fat diet (HFD)-induced metaflammation，and shows anti-inflammatory activity to (10 μM) decreases IL-1β release in human macrophages. INF200 improves glucose and lipid profiles，and attenuates systemic inflammation and biomarkers of cardiac dysfunction (particularly BNP). INF200 also improves myocardial damage-dependent ischemia/reperfusion injury (IRI) in hemodynamic evaluation.
    INF200
  • HY-15601R
    Vesatolimod (Standard) 1228585-88-3
    Vesatolimod (Standard) is the analytical standard of Vesatolimod. This product is intended for research and analytical applications. Vesatolimod (GS-9620) is a potent, selective and orally active agonist of Toll-Like Receptor (TLR7) with an EC50 of 291 nM.
    Vesatolimod (Standard)
  • HY-156297
    β5i-IN-1 3055187-85-1 98%
    β5i-IN-1 is a potent and selective inhibitor of β5i with a IC50 of 8.463 nM. β5i-IN-1 releases TNF-α and IL-6 and influences the transcriptional activity of NF-κB. β5i-IN-1 can be used in study idiopathic pulmonary fibrosis.
    β5i-IN-1
  • HY-156424
    NOX2-IN-1 2648709-25-3 98%
    NOX2-IN-1 (compound 10) is an inhibitor of nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2). NOX2-IN-1 targets the p47phox p22phox protein protein interaction with favorable binding affinities and cellular activities.
    NOX2-IN-1
  • HY-156431
    Anti-inflammatory agent 61 98%
    Anti-inflammatory agent 61 (Compound 5b) is a potent anti-inflammatory agent. Anti-inflammatory agent 61 reduces TNF-α expression in LPS-induced inflammation in RAW 264.7 cells. Anti-inflammatory agent 61 alleviates APAP-induced inflammation in HepG2 cells.
    Anti-inflammatory agent 61
  • HY-156436
    Anti-inflammatory agent 62 98%
    Anti-inflammatory agent 62 is an anti-inflammatory agent. Anti-inflammatory agent 62 alleviate Acetaminophen-induced hepatotoxicity in HepG2 by the regulation of inflammatory and oxidative stress pathways.
    Anti-inflammatory agent 62
  • HY-156468
    Antioxidant agent-17 98%
    Antioxidant agent-17 (compound 59) is a potent inhibitor of superoxide anion generation activity, with an IC50 of 9.06 nM.
    Antioxidant agent-17
  • HY-15651R
    Alvelestat (Standard) 848141-11-7 98%
    Alvelestat (Standard) is the analytical standard of Alvelestat. This product is intended for research and analytical applications. Alvelestat (AZD9668) is an orally bioavailable, affinity and selective inhibitor of neutrophil elastase (NE) with a pIC50 value of 7.9 nM, a Ki value of 9.4 nM and a Kd value of 9.5 nM.
    Alvelestat (Standard)
  • HY-15651S
    Alvelestat-13C,d3 98%
    Alvelestat-13C,d3 (AZD9668-13C,d3) is 13C-labeled Alvelestat (HY-15651).
    Alvelestat-13C,d3
  • HY-156520
    Immunosuppressant-1 1224571-03-2 98%
    Immunosuppressant-1 (Compound 31) inhibits anti-CD3/anti-CD28 co-stimulated T-cell proliferation. Immunosuppressant-1 has immunosuppressive activity, and induces apoptosis by activating caspase-3 and PARP in activated lymph node cells.
    Immunosuppressant-1
Cat. No. Nom du produit / Synonyms Application Reactivity